Tokar A V, Iena L M, Kozymenko T M, Shyshkina O S
Lik Sprava. 1993 Oct-Dec(10-12):34-8.
Effect of three-week treatment with visken on renal and central haemodynamics, renin-angiotensin-aldosterone system (RAAS) and metabolism of electrolytes was studied in 88 elderly and old patients 45 of whom had hypertonic disease (HD) in the second stage and 43 suffered from atherosclerotic (isolated systolic) hypertension (AH). Visken is a highly effective hypotensive beta-adrenoblocker with partially retained sympathomimetic activity. It may be administered as monotherapy to elderly patients with HD as well as to the old and elderly with SH regardless of initial state of systemic and renal haemodynamics. The drug makes blood pressure fall due to its diuretic effect and decrease of general peripheral vascular resistance. It improves renal blood circulation, reduces renal vascular resistance, enhances compromised glomerular filtration but exert no influence upon RAAS. Efficacy of visken diminishes with age. This phenomenon is conditioned by increased refractivity rate and more frequent adverse effects in the old with HD. Latent heart failure, disorders of cardiac rhythm and conductivity (even if mentioned in anamnesis) as well as hypokalemia are contraindications to visken.
对88例老年和高龄患者进行了研究，观察了维斯肯（Visken）三周治疗对肾脏和中枢血流动力学、肾素-血管紧张素-醛固酮系统（RAAS）以及电解质代谢的影响。其中45例为二期高血压病（HD）患者，43例患有动脉粥样硬化（单纯收缩期）高血压（AH）。维斯肯是一种高效的降压β-肾上腺素能阻滞剂，部分保留了拟交感活性。无论全身和肾脏血流动力学的初始状态如何，它都可以作为单一疗法用于HD老年患者以及患有收缩期高血压（SH）的老年人。该药物因其利尿作用和降低总外周血管阻力而使血压下降。它改善肾脏血液循环，降低肾血管阻力，增强受损的肾小球滤过，但对RAAS没有影响。维斯肯的疗效随年龄增长而降低。这种现象是由于老年HD患者的折射率增加和更频繁的不良反应所致。潜在心力衰竭、心律和传导障碍（即使既往病史中有提及）以及低钾血症是使用维斯肯的禁忌证。
